Unknown

Dataset Information

0

Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors.


ABSTRACT: T-cell receptor (TCR)-modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumor antigen escape. In this study, we demonstrate an approach to enhance the in vivo persistence and function of TCR T cells through combination with Amphiphile (AMP) vaccination including cognate TCR T peptides. AMP modification improves lymph node targeting of conjugated tumor immunogens and adjuvants, thereby coordinating a robust T cell-activating endogenous immune response. AMP vaccine combination with TCR T-cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR T-cell monotherapy. Enhanced antitumor efficacy was correlated with simultaneous in vivo invigoration of adoptively transferred TCR T cells and in situ expansion of the endogenous antitumor T-cell repertoire. Long-term protection against tumor recurrence in AMP-vaccinated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by vaccination. AMP vaccination further correlated with pro-inflammatory lymph node transcriptional reprogramming and increased antigen presenting-cell maturation, resulting in TCR T-cell expansion and functional enhancement in lymph nodes and solid tumor parenchyma without lymphodepletion. In vitro evaluation of AMP peptides with matched human TCR T cells targeting NY-ESO-1, mutant KRAS, and HPV16 E7 illustrated the clinical potential of AMP vaccination to enhance human TCR T-cell proliferation, activation, and antitumor activity. Taken together, these studies provide rationale and evidence to support clinical evaluation of combining AMP vaccination with TCR T-cell therapies to augment antitumor activity.

SUBMITTER: Drakes DJ 

PROVIDER: S-EPMC10835214 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors.

Drakes Dylan J DJ   Abbas Abdulraouf M AM   Shields Jacqueline J   Steinbuck Martin P MP   Jakubowski Aniela A   Seenappa Lochana M LM   Haqq Christopher M CM   DeMuth Peter C PC  

Cancer immunology research 20240201 2


T-cell receptor (TCR)-modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumor antigen escape. In this study, we demonstrate an approach to enhance the in vivo persistence and function of TCR T cells through combination with Amphiphile (AMP) vaccination including cognate TCR T peptides. AMP modification improves lymph node targeting of conjuga  ...[more]

Similar Datasets

| S-EPMC8975929 | biostudies-literature
| S-EPMC8012593 | biostudies-literature
| S-EPMC11871467 | biostudies-literature
| S-EPMC11527885 | biostudies-literature
| S-EPMC10044396 | biostudies-literature
| S-EPMC4326267 | biostudies-literature
| S-EPMC4291778 | biostudies-literature
| S-EPMC7178328 | biostudies-literature
| S-EPMC5660298 | biostudies-literature
| S-EPMC8678215 | biostudies-literature